As of January 31, 2020, the non-stimulant medication Guanfacine XR (Intuniv XR) is now covered by OHIP+.
This means that for families whose children are covered by the Ontario Drug Benefit program, Intuniv XR will now be paid for by the Provincial Drug Plan.
Intuniv XR is approved:
“For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
i) As adjunctive therapy to psychostimulants; OR
ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other nonstimulant alternative(s). “
The doctor will have to put the “Limited Use Code” 540 on the prescription to have the medicine covered.
This update from the Ontario Government has more information on this new medicine approval.
